Avinger (AVGR) and HealthTrust Sign Agreement on Lumivascular Technology
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/20/2024
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Jabil falls after placing CEO on paid leave amid internal investigation
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- NVIDIA (NVDA) Shares Extend Drop To 10%, Erasing $212 Billion In Value - Bloomberg
- Tungray Technologies (TRSG) Prices 1.25M Share IPO at $4/sh
- Wells Fargo on Super Micro Computer (SMCI): 'No Positive Preannouncement
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Avinger Signs Agreement with HealthTrust for Lumivascular Technology
September 7, 2016 4:01 PM EDTREDWOOD CITY, Calif., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ: AVGR), a developer of innovative treatments for peripheral artery disease (PAD), today announced it has signed an agreement with HealthTrust. The agreement establishes terms under which members of the HealthTrust group purchasing organization may acquire Avingers portfolio of technologies designed to treat PAD, including Avingers PantherisTM Optical Coherence Tomography (OCT) image-guided atherectomy system, which recently received 510(k) clearance from the United States Food & Drug Administration (FDA). The agreement becomes effective September 15, 2016.
Pantheris is a minimally invasive treatment... More
